The Wellcome Centre for Anti-Infectives Research (WCAIR) aims to tackle the urgent unmet medical need and lack of drug discovery research for Neglected Tropical Diseases (NTDs). WCAIR consolidates the existing world-leading NTD drug discovery expertise within the Drug Discovery Unit, the Mode of Action group and the Parasitology research groups providing a continuum from discovery science to pre-clinical candidate selection.
With an initial focus on visceral leishmaniasis (VL) and Chagas’ disease (CD) the Centre will deliver high-quality pre-clinical drug candidate for each disease. To achieve our research will include:
· Innovate drug discovery approaches for VL and CD, including developing in silico and animal models that have improved prediction of Pharmacokinetic/Pharmacodynamic relationships and clinical efficacy.
· Increased exploitation of novel drug targets, through structure-based drug discovery.
· Develop tool compounds with known pharmacology to enable further understanding of parasite biology.
· Improve the efficiency of drug discovery by establishing groups to facilitate compound scale up, compound purification and formatting.
For further information about WCAIR please click here.